NasdaqHealth CareBiological Products, (No Diagnostic Substances)NEWTON, MA

Acumen Pharmaceuticals, Inc. ABOS

Ask your AI

Estimated market cap $15.48M72.33M shares, shares as of Oct 21, 2026CIK 1576885

Insider trades, 12 mo

0 buys · 48 sells

$625.7K sold, open market

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

26.7% of shares · 25 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q3 2026

What changed in Acumen Pharmaceuticals, Inc.'s latest quarterly report, compared with the one before.

Filed Oct 26, 2026 · Quarter ended Sep 30, 2026

Compared with the 10-Q for the quarter ended Jun 30, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in Acumen Pharmaceuticals, Inc.'s latest quarterly report, compared with the one before.

Loading…

Insider trades

48 in 12 mo

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No open-market insider trades reported since Jun 17, 2026. Insiders have two business days to file.

Recent insider trades

Derrell Porter Director	Jun 17 Form 4 ↗	Sale	−$30.4K 13,040 sh @ $2.33	-92.3%
Derrell Porter Director	Jun 16 Form 4 ↗	Sale	−$29.8K 12,800 sh @ $2.33	-91.2%
Derrell Porter Director	Jun 15 Form 4 ↗	Sale	−$15.2K 6,460 sh @ $2.35	-90.8%
Nathan B. Fountain Director	Jun 9 Form 4 ↗	Sale	−$14.3K 6,400 sh @ $2.23	-92.6%
Derek M. Meisner Chief Legal Officer & Corp Sec	Mar 6 Form 4 ↗	Sale 10b5-1 plan	−$6,813 2,090 sh @ $3.26	-105.7%

All ABOS insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

19.34M shares

64 funds report ABOS. Values checked against market prices.

Funds own 66% of shares (Q2 2026)

96 funds hold the stock.

Q3 2026: 27% · 5,560 of ~8,900 funds reported so far

Q2 202562%
Q3 202559%
Q4 202559%
Q1 202664%
Q2 202666%
Q3 2026 (so far)27%

Q3 2026. 5 new, 25 added to, 13 trimmed, 37 exited since Q2 2026.

Top 13F holders
#
1	Sands Capital Alternatives, LLC 13F ↗	3.72M	$8.3M	unchanged
2	BlackRock, Inc. 13F ↗	2.80M	$6.2M	+12.5%
3	Vanguard Capital Management LLC 13F ↗	1.82M	$4.0M	+8.6%
4	Knollwood Investment Advisory, LLC 13F ↗	1.63M	$3.6M	unchanged
5	Geode Capital Management, LLC 13F ↗	1.15M	$2.6M	+1.1%
6	Hudson Bay Capital Management LP 13F ↗	1.02M	$2.3M	+7.3%
7	Pathstone Holdings, LLC 13F ↗	859,110	$1.9M	unchanged
8	State Street Corp 13F ↗	837,120	$1.9M	+39.4%
9	Renaissance Technologies LLC 13F ↗	614,654	$1.4M	-8.9%
10	Acadian Asset Management LLC 13F ↗	341,825	$754.0K	+26.4%

One of these funds reports its values in thousands of dollars; its figures are shown in dollars.

Download CSV Every fund that holds ABOS, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What Acumen Pharmaceuticals, Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What Acumen Pharmaceuticals, Inc. and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q3 2021	41	—	24.05M	$357.4M
Q4 2021	52	+11	25.59M	$172.9M
Q1 2022	57	+5	27.11M	$106.1M
Q2 2022	47	-10	25.63M	$120.5M
Q3 2022	50	+3	27.76M	$278.4M
Q4 2022	60	+10	29.26M	$158.0M
Q1 2023	61	+1	28.06M	$113.9M
Q2 2023	53	-8	26.33M	$126.6M
Q3 2023	66	+13	43.71M	$181.4M
Q4 2023	67	+1	38.50M	$147.8M
Q1 2024	80	+13	43.54M	$176.3M
Q2 2024	81	+1	43.60M	$105.5M
Q3 2024	73	-8	43.67M	$107.8M
Q4 2024	80	+7	42.53M	$73.2M
Q1 2025	81	+1	40.27M	$44.8M
Q2 2025	71	-10	37.61M	$43.6M
Q3 2025	69	-2	35.74M	$61.1M
Q4 2025	71	+2	35.66M	$75.2M
Q1 2026	84	+13	46.00M	$108.5M
Q2 2026	96	+12	47.86M	$127.8M
Q3 2026	64	-32	19.34M	$38.2M

Each point is a quarter-end, from Q3 2021 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (00509G209). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q3 2021) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes2 in 12 mo 8-K events4 in 90 days PatentsNone on record Short interestFINRA · updated Oct 15 Planned insider salesForm 144 · 44 in 12 mo Executive payNone on record Wikipedia attentionNone on record SEC enforcementNone on record Clinical trials1 active IPO history1 registration Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: Acumen Pharmaceuticals, Inc.
Address: 1210-1220 WASHINGTON STREET, SUITE 210, NEWTON, MA 02465
Phone: 617-344-4190
Fiscal year ends: Dec 31
Filer category: emerging growth company
Incorporated in: DE
Listed as: ABOS (Nasdaq)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$0.214−$0.00 (−1.83%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $0.2101 · High $2.38Nov 13, 2026

Aug 13, 2026Low $0.2101 · High $3.19Nov 13, 2026

Nov 13, 2025Low $0.2101 · High $3.37Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.